GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alexza Pharmaceuticals Inc (OTCPK:ALXA) » Definitions » Total Liabilities

Alexza Pharmaceuticals (Alexza Pharmaceuticals) Total Liabilities : $84.92 Mil (As of Mar. 2016)


View and export this data going back to 2006. Start your Free Trial

What is Alexza Pharmaceuticals Total Liabilities?

Alexza Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2016 was $84.92 Mil.

Alexza Pharmaceuticals's quarterly Total Liabilities declined from Sep. 2015 ($95.07 Mil) to Dec. 2015 ($86.39 Mil) and declined from Dec. 2015 ($86.39 Mil) to Mar. 2016 ($84.92 Mil).

Alexza Pharmaceuticals's annual Total Liabilities increased from Dec. 2013 ($71.05 Mil) to Dec. 2014 ($113.21 Mil) but then declined from Dec. 2014 ($113.21 Mil) to Dec. 2015 ($86.39 Mil).


Alexza Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Alexza Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alexza Pharmaceuticals Total Liabilities Chart

Alexza Pharmaceuticals Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 58.30 37.98 71.05 113.21 86.39

Alexza Pharmaceuticals Quarterly Data
Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 94.84 96.54 95.07 86.39 84.92

Alexza Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Alexza Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2015 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=58.198+(21.127+3.652
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+3.412+0)
=86.39

Total Liabilities=Total Assets (A: Dec. 2015 )-Total Equity (A: Dec. 2015 )
=14.731--71.658
=86.39

Alexza Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2016 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=60.352+(20+1.5
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+3.066+0)
=84.92

Total Liabilities=Total Assets (Q: Mar. 2016 )-Total Equity (Q: Mar. 2016 )
=10.583--74.335
=84.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alexza Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Alexza Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Alexza Pharmaceuticals (Alexza Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Alexza Pharmaceuticals Inc was incorporated in the state of Delaware on December 19, 2000 as FaxMed, Inc. In June 2001, it changed the name to Alexza Corporation and in December 2001 it became Alexza Molecular Delivery Corporation. In July 2005, it changed the name to Alexza Pharmaceuticals, Inc. It is a pharmaceutical company, engaged in the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. ADASUVE is its only approved product & there is one product candidate in active development, AZ-002 (Staccato alprazolam), which is being developed for the treatment of acute repetitive seizures, sometimes called cluster seizures or ARS. ADASUVE, or Staccato loxapine, and its product candidates are based on its proprietary technology, the Staccato system. The Staccato system vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. Because of the particle size of the aerosol, the drug is quickly absorbed through the deep lung into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous, or IV, administration but with greater ease, patient comfort and convenience. The pharmaceutical and biotechnology industries are intensely competitive. Many pharmaceutical companies, biotechnology companies, public and private universities, government agencies and research organizations are actively engaged in research and development of products targeting the same markets as ADASUVE and its other product candidates. The names "Alexza Pharmaceuticals," "Alexza," "Staccato" and "ADASUVE" are trademarks of the Company. It helds 195 issued and allowed U.S. and international patents. The testing, manufacturing, labeling, advertising, promotion, distribution, export and marketing of the Company's product candidates are subject to extensive regulation by governmental authorities in the United States and other countries.
Executives
Deepika Pakianathan director 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Gordon Ringold director 325 EAST MIDDLEFIELD AVENUE, MOUNTAIN VIEW CA 94043
J Kevin Buchi director 41 MOORES ROAD, FRAZER PA 19355
Thomas Braxton King director, officer: President & CEO 91 JAMES AVENUE, ATHERTON CA 94027
Joseph L Turner director 10505 ROSELLE STREET, SAN DIEGO CA 92121
Mark K Oki officer: Former SVP, CFO, Secretary C/O ALEXZA PHARMACEUTICALS INC, 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Robert A Lippe officer: EVP, Operations & COO C/O ALEXZA PHARMACEUTICALS, INC., 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
James V Cassella director, officer: Former EVP, R&D and CSO 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Samuel D Colella other: Former Director ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Alan D Frazier director
Symphony Capital Gp, L.p. 10 percent owner, other: See Footnote 2 and Remarks C/O SYMPHONY CAPITAL LLC, 875 THIRD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Harri V Taranto 10 percent owner, other: See Footnote 2 and Remarks C/O SYMPHONY CAPITAL LLC, 875 THIRD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Symphony Gp, Llc 10 percent owner, other: See Footnote 2 and Remarks C/O SYMPHONY CAPITAL LLC, 875 THIRD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Symphony Capital Partners Lp 10 percent owner, other: See Footnote 2 and Remarks C/O SYMPHONY CAPITAL LLC, 875 THIRD AVENUE, NEW YORK NY 10022
Mark Kessel 10 percent owner, other: See Footnote 2 and Remarks 950 PARK AVE APT. 11A, NEW YORK NY 10028

Alexza Pharmaceuticals (Alexza Pharmaceuticals) Headlines